Why the study?
Severe tricuspid regurgitation is an undertreated pathology with high mortality, and traditional surgical options carry up to 10% postprocedural mortality.
This review serves as a procedural guide detailing the techniques and steps for utilizing various novel transcatheter devices to treat severe tricuspid regurgitation.
Answers are grounded in this paper and cite their sources.
Offers procedural reference for transcatheter tricuspid interventions; leaves open need for outcome validation trials.
Severe tricuspid regurgitation (TR) is an undertreated common pathology associated with significant morbidity and mortality. Classically, surgical repair or valve replacement were the only therapeutic options and are associated with up to 10% postprocedural mortality. Transcatheter tricuspid valve interventions are a novel and effective therapeutic option for the treatment of significant TR. Several devices have been developed with different mechanisms of action. They are classified as annuloplasty devices, replacement devices, caval valve implantation and coaptation devices. In this review, we provide a step-by-step description of the procedural steps and techniques of every device along with video support.
No takes yet. Share an insight, caveat, or question.
Matli et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: